NCT05849558View on ClinicalTrials.gov

Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients

PHASE4UnknownINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Chronic Liver Disease
Interventions
DRUG

Ursoplus

Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)

DRUG

UDCA 250mg

UDCA 250mg alone

OTHER

Placebo

Placebo alone

Trial Locations (1)

Unknown

RECRUITING

Air Force Specialized Hospital, Cairo

Sponsors
All Listed Sponsors
lead

MinaPharm Pharmaceuticals

INDUSTRY